Transcript Pregnancy and MDR-TB - DR TB Training Network

Pregnancy and MDR-TB
Session 7
1
Tuberculosis infection during pregnancy
• TB disease occurs in a small but definite percentage of
pregnant woman.
• Relative immuno-compromise may allow latent infection to
progress to active TB disease.
• Pregnant women with active TB have a higher risk of
complications (pre-eclampsia, vaginal hemorrhage and fetal
loss).
USAID TB CARE II PROJECT
Options for treatment of TB during
pregnancy
• Need to consider risks and benefits for the mother and fetus.
– Option 1: Stop or delay MDR-TB treatment
• Can be considered if TB disease is not an immediate threat
to the health of the patient or if TB is diagnosed in the late
stages of pregnancy.
– Option 2: Terminate the pregnancy
• May be considered in cases that require injectable agents for
cure.
– Option 3: Continue treatment while pregnant
• Treatment is challenging but not contraindicated.
• There is minimal data about the safety of second-line antituberculous agents during pregnancy.
USAID TB CARE II PROJECT
Pregnancy and MDR-TB
Retrospective review of 3089 patients started on MDR-TB treatment
from July 1996 to December 2005 in Peru:
– 1033 (33.4%) of these patients were women of child‐bearing age
(age, 15–45 years);
– 38 (3.6%) were reported to be pregnant while receiving treatment
for MDR‐TB;
– 14 women experienced no changes in their treatment regimen
during pregnancy;
– MDR‐TB treatment was suspended after determination of
pregnancy for 14 (36.8%) women; and
– 13 women (34.2%) subsequently resumed treatment after
discussion with a physician a median of 1.9 weeks (IQR, 1.0–4.6
weeks) after suspension of treatment.
Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment
outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.
USAID TB CARE II PROJECT
Treatment outcomes
Treatment
outcome
Cure
Dead
21
2
23 (60.5)
5
5 (13.2)
Death
Default
In treatment
3
Failure
2
1
In treatment
24 (63.2)
8 (21.1)
5 (13.2)
1
2 (5.3)
2
2 (5.3)
Not known
Total (%)
Unknown
Total
(%)
Healthy
3 (7.9)
1
1 (2.6)
3 (7.9)
38 (100.0)
Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment
outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.
USAID TB CARE II PROJECT
Children
• Follow‐up data were available for 26/38 children.
– 2 children were treated for latent TB (IPT per NTP protocol);
– 1 child was treated successfully for active MDR-TB at 19 months
of age based on the DST of the mother;
– 1 child died of pneumonia shortly after birth (no TB involvement
was reported);
– 25 children are currently healthy, including those who were
treated for latent or active TB; and
– 2 children have minor health problems:
• 1 child was born with testicular malformation (unlikely to be related
to exposure to second-line TB drugs in utero;
• 1 child has idiopathic growth retardation but has otherwise remained
healthy.
Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment
outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.
USAID TB CARE II PROJECT
Timing of Treatment Initiation
• Ideally avoid treatment during the first trimester.
– If the clinical state is severe enough to pose a threat to the life of
the patient, consider treatment during the first trimester.
• Start treatment during the second or third trimester so that the
patient will be smear and culture negative at the time of giving
birth.
USAID TB CARE II PROJECT
Safety Classification of Medications During
Pregnancy
• A = safety established in human studies.
• B = safety presumed based on animal studies.
• C = safety uncertain; no human or animal studies reveal an
adverse effect.
• D = safety uncertain; evidence of risk but use is justified in
certain circumstances.
USAID TB CARE II PROJECT
Isoniazid
• Safety class C
• Experience with patients suggests safety
• Pyridoxine (vitamin B6) should be used during pregnancy
USAID TB CARE II PROJECT
Rifampicin
• Safety class C
• Experience with patients suggests safety
USAID TB CARE II PROJECT
Ethambutol
• Safety class B
• Experience with pregnant patients suggests safety
USAID TB CARE II PROJECT
Pyrazinamide
• Safety class C
• Formal studies are limited but there is much clinical experience
USAID TB CARE II PROJECT
Streptomycin
• Safety class D
– Documented toxicity to the developing fetal ear (8-11%). Toxicity
is higher in the first trimester.
• Risks and benefits should be carefully considered.
• Use should be limited to severe cases when clinical status and
drug resistance warrants use.
USAID TB CARE II PROJECT
Kanamycin, Amikacin
• Safety class D
– Documented fetal ototoxicity
– With use of KM, 2.3%
• Risks and benefits should be carefully considered.
USAID TB CARE II PROJECT
Capreomycin
• Safety class C
– Less ototoxicity in adults compared with the aminoglycosides.
• If the risk of morbidity or mortality from TB during pregnancy is
high, it is preferable to use CM in place of an aminoglycoside.
USAID TB CARE II PROJECT
Fluoroquinolones
• Safety class C
– No documented teratogenic effects in human studies. Mean
duration given 2-4 weeks.
– In 240 pregnant patients, no congenital effects observed.
• Data regarding the prolonged use in pregnant patients is
limited, but benefits likely outweigh risks.
USAID TB CARE II PROJECT
Ethionamide
• Safety class C
– Animal studies (high doses);
– 2 studies of 47 cases and 1 of 70 cases without adverse effects;
– In another study, 7 of 23 children had congenital malformations.
• The use is controversial given the mixed data; if an adequate
regimen cannot be constructed without it, the use of
ethionamide is justified.
• Given its gastrointestinal side effects, nausea and vomiting
during pregnancy may be aggravated.
USAID TB CARE II PROJECT
Cycloserine
• Safety class C
– Few studies in pregnant patients
– Animal studies do not document toxicity
USAID TB CARE II PROJECT
PAS
• Safety class C
• No data to show teratogenicity
USAID TB CARE II PROJECT
Breastfeeding
• First-line medications have a variable concentration in
breast milk.
• Injectables not absorbed by infant (minimal possibility of
toxicity for breastfeeding infant).
• Effects of other medications during breastfeeding unknown.
• Advise mother that breastfeeding is not prohibited but she
should consider the risks and benefits of the decision.
USAID TB CARE II PROJECT
Family Planning
• Of 38 Peruvian women who received MDR-TB therapy while
pregnant:
– 3 patients (7.9%) were pregnant at the initiation of MDR‐TB
therapy and had been pregnant for a median of 8.2 months (IQR,
7.3–8.2 months).
– 35 patients (92.1%) became pregnant while receiving treatment;
these patients became pregnant a median of 9.7 months (IQR,
4.4–17.0 months) after treatment initiation.
Palacios E, Dallman R, Muñoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment
outcomes of 38 cases in Lima, Peru. Clin Infect Dis 2009;48(10):1413-9.
USAID TB CARE II PROJECT
Recommendations
• The best way to deal with MDR-TB and pregnancy is to
prevent it.
• All women of child-bearing age should be offered a reliable
method of family planning by the health care worker providing
MDR-TB treatment (integrated family planning).
– A “reliable method” excludes abstinence and condoms.
– Depo-Provera can be provided at 3 month intervals during the
clinic visit.
USAID TB CARE II PROJECT
Recommendations
• Provide individualized care based on risks and benefits to the
patient and fetus.
• The patient should be involved in therapeutic decisions.
• If pregnancy occurs during treatment and the patient is stable,
treatment can be deferred until the second trimester unless
there is clinical deterioration.
USAID TB CARE II PROJECT
Recommendations
• During the first 20 weeks of pregnancy, avoid the injectable if
possible.
– Exception: if the risk of morbidity or mortality is high, an
injectable agent should be used (preferably CM).
• There is limited evidence, but clinical experience has shown
that cycloserine, fluoroquinolones, and PAS may be used in
pregnant patients.
USAID TB CARE II PROJECT
Recommendations
• Ethionamide and prothionamide
– Some cases of congenital fetal defects;
– Not enough data to confirm the safety or risks of these
medications.
• Use pyridoxine (vitamin B6) in all pregnant patients.
• Breastfeeding is permissible, however the risks and benefit
should be discussed with the patient.
USAID TB CARE II PROJECT